Jørgen Drejer (born 1955) is a neurobiologist with more than 30 years of experience in discovering and developing novel approaches to modulate pathways within the brain. His research has led him to found multiple companies and publish more than 75 scientific articles.
Drejer founded Saniona in 2011 and served as founding Chief Executive Officer until January 2020, when he assumed the role of Chief Scientific Officer. Prior to founding Saniona, he co-founded NeuroSearch A/S in 1989, holding various leadership roles including deputy CEO and head of research over a 20-year period in which NeuroSearch became a major European biotechnology company. Drejer holds a PhD in neurobiology from the University of Copenhagen.
Drejer currently serves as a member of the Board of Directors for Saniona and 2CureX. He has served on the Saniona board since 2014 and served as a board member of Saniona A/S since 2012. He is also a Member of the Danish Academy of Engineering Science. He previously served as a member of the Board of Directors for NeuroSearch A/S, Origio A/S, NsGene A/S, Atonomics A/S, Azign Bioscience A/S, Ellegaard Göttingen Minipigs ApS, Force Technology and Monta Biosciences A/S.
Drejer is not independent in relation to Saniona and its management but is independent in relation to major shareholders. He holds 2,364,711 shares in Saniona and 77,000 warrants in the warrant program 2020/2024.
Board member since 2018
Anna Ljung (born 1980) is CEO of Moberg Pharma AB, a publicly-traded Swedish pharmaceutical company focused on drug delivery within dermatology. In addition to serving as CEO of Moberg Pharma, she also currently serves as Chairman of OncoZenge AB, a publicly-traded Swedish pharmaceutical company, and Chairman of Moberg Derma Incentives AB.
Prior to becoming CEO of Moberg, Ljung served as the company’s Chief Financial Officer for 13 years, and prior to that she was CFO at Athera Biotechnologies AB and Controller for Lipopeptide AB. She also previously was an independent consultant within the field of technology licensing. Ljung received her M.Sc. in Economics and Business Administration from Stockholm School of Economics. Additional previous board positions have included MPJ OTC AB and Advantice Health AB.
Ljung is independent in relation to both Saniona and its management as well as major shareholders. She holds 4,629 shares; 4,000 warrants in the warrant program 2018/2024; 4,000 warrants in the warrant program 2019/2023; and 77,000 warrants in the warrant program 2020/2024.
Board member since 2015 (board member of Saniona A/S since 2016)
Carl Johan Sundberg (born 1958) is a physician and professor with extensive experience in healthcare entrepreneurship, investment and communication. He currently serves as the Chair of the Department of Learning, Informatics, Management & Ethics at the Karolinska Institutet, Stockholm. He also currently serves as a board member for Arne Ljungqvist Anti-doping Foundation AB and Medkay Konsulting AB.
Sundberg’s affiliation with Karolinska Institutet spans over 30 years and includes work in molecular and applied exercise physiology, medical innovation and bioentrepreneurship. He also cofounded and managed Karolinska Investment Fund, a EUR 60 million biomedicine venture capital fund. His communications experience includes previous working periods with Svenska Dagbladet (a large morning daily) and ABC Television, U.S. He serves in membership and advisory positions with the Royal Swedish Academy of Engineering Sciences, Swedish Professional Associations for Physical Activity, Research!Sweden and the International Olympic Committee Medical Commission. Sundberg earned his medical degree and Ph.D. from Karolinska Institutet. Previous board positions include Cobra Biologics Holding AB, Hypercure Medical AB, Karolinska Development AB and NsGene A/S.
Sundberg is independent in relation to both Saniona and its management as well as major shareholders. He holds 9,800 shares; 4,000 warrants in the warrant program 2018/2024; 4,000 warrants in the warrant program 2019/2023; and 77,000 warrants in the warrant program 2020/2024.